Interesting paper evaluating BindCraft (a generative AI tool for making small proteins) for peptide generation. BindCraft was found to work well for generating peptides to bind certain protein targets, while it failed completely for other protein targets. The protein targets for which experimental peptide hits were discovered were the ones with more structural data available, likely reflecting BindCraft’s training data.
This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.
A new research paper documents the outcomes of five volunteers who continued to receive 40Hz light and sound stimulation for around two years after participating in an MIT early-stage clinical study of the potential Alzheimer’s disease (AD) therapy. The results show that for the three participants with late-onset Alzheimer’s disease, several measures of cognition remained significantly higher than comparable Alzheimer’s patients in national databases. Moreover, in the two late-onset volunteers who donated plasma samples, levels of Alzheimer’s biomarker tau proteins were significantly decreased.
The three volunteers who experienced these benefits were all female. The two other participants, each of whom were males with early-onset forms of the disease, did not exhibit significant benefits after two years. The dataset, while small, represents the longest-term test so far of the safe, noninvasive treatment method (called GENUS, for gamma entrainment using sensory stimuli), which is also being evaluated in a nationwide clinical trial run by MIT-spinoff company Cognito Therapeutics.
“This pilot study assessed the long-term effects of daily 40Hz multimodal GENUS in patients with mild AD,” the authors wrote in an open-access paper in Alzheimer’s & Dementia: TheJournal of the Alzheimer’s Association. “We found that daily 40Hz audiovisual stimulation over 2 years is safe, feasible, and may slow cognitive decline and biomarker progression, especially in late-onset AD patients.”
Discount Links/Affiliates: Blood testing (where I get the majority of my labs, for those who blood test with Quest): https://www.ultalabtests.com/partners…
Could AI and biology trigger a longevity singularity? Dr. Natasha Vita-More maps the AI-biology longevity flywheel and three frontiers reshaping longevity culture: nanorobots, biostasis, and AI prosthetics.
As longevity grows from a scientific movement into a global industry and cultural force, Natasha presents her Three Frontiers of Longevity Culture:
• Nanorobots — precision repair, sensing, and therapeutic delivery at the cellular scale. • Biostasis — preserving cells, tissues, organs, and potentially more complex biological systems. • AI prosthetics — intelligent, adaptive technologies moving from restored function toward expanded human capability.
We separate what is possible today from what is experimental and what remains a long-term vision. How close are we to medical nanorobots? Could organ banking become the bridge to human biostasis? When does an intelligent prosthetic stop being a tool and begin becoming part of the person?
The conversation also examines the AI–biology longevity flywheel: how artificial intelligence could accelerate biological discovery, diagnostics, drug development, personalized interventions, regenerative medicine, and the broader effort to extend healthy human life.
Using cryo-electron microscopy and electrophysiology, this study explains the structural basis for Ca2+ permeation and Mg2+ block in NMDA receptors and identifies a surrounding lipid network that may tune Mg2+-dependent voltage sensitivity.
